期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗心律失常药物:从经验到循证再到分子机制治疗 被引量：4

下载PDF
导出
摘要 近年来，导管消融技术的迅猛进展使得多种快速心律失常得以根治，但抗心律失常药物仍是大多数心律失常的首选治疗和最主要的治疗选择。人们致力于研发新型抗心律失常药物或对传统抗心律失常药物进行再认识乃至结构改造，以提高药物的疗效和安全性。
作者 张海澄
机构地区 北京大学人民医院心内科
出处 《中国心脏起搏与心电生理杂志》 北大核心 2010年第5期379-381,共3页 Chinese Journal of Cardiac Pacing and Electrophysiology
关键词 抗心律失常药物 治疗 分子机制 循证 快速心律失常 消融技术 结构改造 安全性
分类号 R972.2 [医药卫生—药品]
  • 相关文献

参考文献20

  • 1Schumacher SM, McEwen DP, Zhang L, et al.Antiarrhythmic drug-induced internalization of the atrial-specific K^+ channel Kv1.5[J].Circ Res,2009,104:1 390.
  • 2Watanabe H, Chopra N, Laver D, et al.Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans[J].Nat Med,2009,15:380.
  • 3Singh BN, Connolly SJ, Crijns HJ, et al.EURIDIS and ADONIS Investigators.Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter[J].N Engl J Med,2007,357:987.
  • 4Hohnloser SH, Crijns HJ, van Eickels M, et al.Effect of dronedarone on cardiovascular events in atrial fibrillation [J].N Engl J Med, 2009, 360 (7): 668.
  • 5Kober L, Torp-Pedersen C, McMurray JJ, et al.Increased mortality after dronedarone therapy for severe heart failure[J].N Engl J Med, 2008, 358 (25): 2 678.
  • 6Heuzey JYL, Ferrari GM, Radzik D, et al.A Short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS Study[J].J Cardiovasc Electrophysiology, 2010,21(6): 597.
  • 7Gautier P, Guillemare E, Djandjighian L, et al.In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin Ⅱ effects[J].J Cardiovasc Pharmacol,2004,44:244.
  • 8Camm AJ, Kirchhof P, Lip GH, et al.Guidelines for the management of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)[J].European Heart Journal,doi:10.1093/eurheartj/ehq278.
  • 9Eldstrom J, Wang Z, Xu H, et al.The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels[J].Mol Pharmacol,2007,72:1 522.
  • 10Dorian P, Pinter A, Mangat I, et al.The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans[J].Jcardiovasc Pharmacol,2007,50:35.

同被引文献48

  • 1葛少勇,孙惠芳.天王补心丹配合西药治疗心律失常35例[J].陕西中医,2004,25(7):589-590. 被引量：10
  • 2陶建国,张振宇.苓桂术甘汤临床应用举隅[J].云南中医中药杂志,2006,27(6):26-26. 被引量：2
  • 3Haraguchi R, Ashihara T, Namba T, et al. Transmural dispersion of repolarization determines scroll wave behavior during ventricular tachyarrhythmias[J]. Circ J, 2011,75 ( 1 ) 80 88.
  • 4Viswanathan P C, Rudy Y. Cellular arrhythmogenic effects of congenital and acquired long QT syndrome in the heterogene ous myocardium[J]. Circulation,2000,101(10) :1192-1198.
  • 5Johnson D M,de Jong M M J ,Crijns H J G M,et at. Reduced ventricular proarrhythmic potential of the novel combined ion channel blocker AZD1305 z,ersus dofetilide in dogs with remodeled hearts[J]. Circ Arrhythm Electrophysiol,2012,5 (1):201-209.
  • 6Fauchier L, Pierre B, de Labriolle A, el al. Antiarrhythmic effect of statin therapy and atrial fibrillation. A meta analysis of randomized controlled tr a s[J]. J Am Coll Cardiol. 2008, 51(8) :828-835.
  • 7Vermes E, Tardif J C, Bourassa M G, et a l. Enalapril decrea- ses the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials [ J ]. Circulation, 2003,107(23) :2926-2931.
  • 8Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a histo- ry of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study[J]. J Am Coil Cardioh 2005,45(5):705-711.
  • 9Burashnikov A,Barajas Martinez H,Hu D,etal. Alrial selcc rive prolongation of refractory period with AVE0118 is dueprincipally to inhibition of sodium channel activity[J]. J Card iovasc Pharmacol, 2012. Epub ahead of print.
  • 10Scirica B M, Morrow D A, Hod H,et al. Effect of ranolazine, an amianginal agent with novel electrophysinlogical proper- ties, on the incidence of arrhythmias in patients with non ST segment elewltion acute coronary syndrome: results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 ( MERLIN TIMI 36) randomized controlled trial[J]. Circulation, 2007,116 (15) : 1647-1652.

引证文献4

二级引证文献28

中国心脏起搏与心电生理杂志
2010年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部